Articles tagged with Ovarian Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A new study confirms that opportunistic salpingectomy (OS), which involves removing fallopian tubes during hysterectomy or tubal ligation, reduces the risk of serous ovarian cancer by nearly 80%. The procedure leaves ovaries intact, preserving hormone production and minimizing side effects.
A study published in JAMA found that salpingectomy significantly lowers the risk of developing tubo-ovarian carcinoma. The procedure, typically performed during unrelated pelvic or abdominal surgery, is now recommended as a preventive measure for eligible women.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Five IIT researchers receive Proof-of-Concept grants to develop innovative health technologies, including a smart microscope and edible pills. These projects aim to tackle cancer, dyslexia, and diagnostics with cutting-edge technologies like quantum computing and near-infrared photonic chips.
Melanie Rutkowski's pioneering research may lead to novel immunotherapy treatments for ovarian cancer by understanding how faulty cellular signaling interacts with the microbiome. The grant aims to enhance immune system's ability to kill cancer cells and improve patient outcomes.
Researchers found that ovarian cancer transforms the omentum into an environment that favors tumor spread. The study analyzed tissue samples from 15 patients and created a cell atlas of the omentum in diseased and healthy states.
A new study validates OVCAR3 as a reliable model for high-grade serous ovarian carcinoma, providing insights into disease behavior and potential therapeutic targets. The research also explores the effects of repurposed drugs on ovarian cancer cells, revealing promising results for treatment responses.
UT Health San Antonio received $3 million in CPRIT grants to expand access to preventive salpingectomy, test novel methods to prevent liver cancer, and advance treatment for therapy-resistant metastatic breast cancer. These projects aim to improve cancer prevention, diagnosis, and treatment in South Texas.
Studies show that patients with advanced ovarian and metastatic breast cancer dedicate approximately 7 hours per week to cancer-related tasks. Most participants report performing these tasks daily, impacting their time burden. The use of a mobile app facilitated the collection of detailed time-use data.
Lab studies found that a combination of THC and CBD kills ovarian cancer cells without harming healthy cells. The compounds may prevent metastasis and have minimal toxic effects, making them a promising alternative to current treatments.
Sofetabart mipitecan, a novel ADC targeting folate receptor alpha, shows robust clinical activity in patients with platinum-resistant ovarian cancer. The GOG-3133/ FRAmework-01 phase 3 study aims to expand treatment options for recurrent ovarian cancer and address the need for more effective therapies.
Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.
A UTEP research team found that Claudin-4, a protein increasing in ovarian cancer, may help tumors survive and hide from the immune system. Targeting Claudin-4 with a peptide and PARP inhibitor slows tumor growth and enhances the immune system's ability to fight cancer.
Researchers have identified a protein complex that drives T cell exhaustion in tumors and show that disrupting it can revive exhausted anti-tumor CTLs. The study's findings offer new hope for improving the efficacy of cancer immunotherapy.
Australian scientists have developed a new blood test that can identify women with ovarian cancer more likely to benefit from PARP inhibitor therapy, offering hope for more effective treatment. The test measures immune biomarkers and predicts which patients will respond to treatment.
MIT researchers have developed new nanoparticles that deliver the immune-stimulating molecule IL-12 directly to ovarian tumors, eliciting a strong response and clearing tumors in over 80% of mice. This treatment combines with checkpoint inhibitors to launch an attack on cancer cells without causing side effects.
Scientists have identified a new biomarker, F2R, which could improve ovarian cancer diagnosis and treatment. Elevated F2R levels are associated with shorter life spans, making it a valuable prognostic indicator.
Black and Asian patients were underrepresented in clinical trials, leading to worse survival outcomes compared to white counterparts, despite similar progression-free survival rates. Equitable enrollment is crucial for access to cutting-edge treatments and long-term equity in cancer care.
A major study of breast, cervical, and ovarian cancers found significant inequalities in global care, with many low- and middle-income countries (LMICs) diagnosing cancer at a later stage. Surgery was offered consistently, but treatment consistency varied, with LMICs often choosing mastectomy over breast-conserving surgery.
MSK researchers have developed a new method to study treatment resistance in high-grade serous ovarian cancer. By analyzing blood samples from 18 patients, they identified subpopulations of cancer cells with distinctive genetic features that contribute to recurrence. This approach may help develop targeted treatments for specific vulne...
Researchers engineered CAR T cells to produce a fusion of IL-12 cytokine and a PD-L1 blocker, boosting immune activity against solid tumors. The modified cells were found to be highly effective in shrinking ovarian and prostate tumors while minimizing side effects.
The loss of Trp53 leads to more aggressive tumor growth and weaker immune responses in ovarian cancer. Researchers developed a mouse model that mimics human HGSC, showing how the disease progresses and evades the immune system.
Researchers identified NBL1 as a key driver of ovarian cancer metastasis through its activation of the Jak/Stat3 pathway. NBL1 expression levels strongly correlated with advanced clinical stage and poor survival outcomes.
Researchers developed Ovatools, a tool combining blood test results and age to identify women at higher risk of ovarian cancer. The approach is accurate for women over 50 and represents good value for the NHS, detecting more cancers earlier while remaining within affordability thresholds.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
A retrospective cohort study found that GLP-1 receptor agonists may reduce overall cancer risk, including lower risks of endometrial and ovarian cancers, among patients with obesity or overweight. However, these medications may also increase the risk of kidney cancer, highlighting the need for longer-term follow-up.
A 36-year-old woman was diagnosed with non-gestational ovarian choriocarcinoma, a rare and aggressive tumor that shares symptoms with pregnancy. She received chemotherapy and showed complete response to treatment.
Researchers identify three tumor-reactive T cell subpopulations that exhibit selective expansion in ovarian cancer patients. CD8+ TCF7-expressing Tpex cells demonstrate self-renewal capacity and generate stem-like progenies, which may enhance persistence and specificity in current TIL therapy.
A significant proportion of patients with high-grade serous ovarian cancer missed genetic testing and surgical prevention opportunities due to limited effective screening options and treatment limitations. The study emphasizes the importance of addressing these gaps to eradicate this aggressive form of ovarian cancer.
A new multi-institutional study confirmed that the NSD2 protein can be targeted with a new drug, blocking it effectively reprogrammed DNA structure, reversed and prevented cancer growth in preclinical models of KRAS-mutant lung and pancreatic cancers. Targeting the brain-liver pathway with electronic wearables could prevent cancer-asso...
A 23-year bibliometric analysis reveals key hotspots in ovarian cancer care, including quality of life, surgery, and nursing health. The study emphasizes the need for future research on psychological well-being and integrated care models to improve outcomes for women with ovarian cancer.
Researchers developed a novel radioimmunotherapy that successfully eliminated cancer stem cells (CSCs) in preclinical models of ovarian cancer. The therapy, targeting CSC-associated biomarkers L1CAM + /CD133 + , showed significantly increased cytotoxicity compared to existing treatments.
A study of ovarian tumor immune landscapes reveals four distinct immunologic subtypes, with those with T cells surviving longer and having better outcomes. The researchers also found that myeloid cells play a key role in reestablishing the immune landscape upon recurrence.
Diana Hargreaves will receive $1 million to advance her project on improving immunotherapy in patients with pancreatic cancer. Her previous work identified better drug targets for cancers with SWI/SNF mutations, leading to breakthroughs in treating difficult-to-treat cancers.
Researchers at MD Anderson identified specific co-mutations in KRAS-mutant non-small cell lung cancer (NSCLC) that improve treatment response to ATR inhibitors. Additionally, chemotherapy was found to drive changes to the genome and clonal architecture of blood stem cells, increasing the risk of secondary malignancies.
A team led by University of Houston engineer Tianfu Wu aims to find better biomarkers for ovarian cancer using autoantibodies and machine learning. By detecting ovarian cancer earlier, mortality rates could be reduced by 10-30%.
A new study found that over 65% of ovarian cancer tumors exhibit whole-genome doubling, making them more resistant to treatments. WGD-high tumors suppress the immune response by repressing key pathways.
A retrospective analysis of 22 patients with brain metastases from ovarian cancer treated with Gamma Knife stereotactic radiosurgery (GKSRS) showed a high intracranial tumor control rate of 97.1% at 12 months post-treatment. No acute or chronic toxicity was observed in the study.
A new combination treatment strategy selectively targets ovarian tumor cells, reducing growth in preclinical models. The approach identifies effective regimens to treat genetically diverse cancers by blocking specific growth signaling pathways.
A new genetic marker, PPP2R1A mutations, has been linked to improved survival rates for patients treated with immunotherapy in ovarian and other cancers. Targeting this biomarker may further enhance treatment outcomes, suggesting a potential new therapeutic target.
Mayo Clinic researchers have detected early, hidden changes in cells lining a patient's fallopian tubes, revealing signals that may point to the first signs of ovarian cancer. The study uses cutting-edge single-cell technologies to uncover developmental alterations in epithelial cells that signal high risk for lethal ovarian cancer.
The Association for Molecular Pathology publishes guidelines for detecting homologous recombination deficiency (HRD) in cancer. The report includes recommendations for clinical laboratories, addressing technical aspects of genomic instability and HRD analysis.
Researchers employed a novel validation-based insertional mutagenesis technique to identify genes conferring carboplatin resistance in human epithelial ovarian cancer cells. HN1L was found to enhance resistance by activating NF-κB signaling, and targeting this gene may represent a promising strategy for overcoming platinum resistance.
A new study explains how the gene CDK12 drives high-grade serous tubo-ovarian carcinoma, a rare and aggressive form of ovarian cancer. Researchers discovered that inactivating CDK12 triggers an immune cell response and identified a partner gene, CDK13, as a target for a degrader or inhibitor.
Researchers found that it took 13 years for cervical cancer screenings to halve among women over 65, and even longer for prostate cancer screenings to decrease significantly. The study emphasizes the need for more effective tracking mechanisms to identify and reduce inappropriate screening practices.
The ESMO Gynaecological Cancers Congress 2025 will convene in Vienna, Austria, from June 19-21, featuring novel data on immunotherapy combinations and emerging treatment strategies for rare gynaecological cancers. The congress will also explore innovative approaches using antibody-drug conjugates.
Researchers discovered that blocking PRDX1 protein can make ovarian cancer cells more responsive to DNA-damaging platinum therapies. The study suggests targeting PRDX1 could be a viable strategy to improve chemotherapy efficacy.
Weill Cornell Medicine researchers Dr. Juan R. Cubillos-Ruiz and Dr. David Lyden have been awarded a $750,000 grant to study ovarian cancer, with a focus on harnessing immune cells and detecting the disease earlier. Their research aims to develop innovative strategies for eliminating metastatic tumors and preventing recurrence.
A real-world study of 1,752 patients with stage III or IV ovarian cancer found that adding bevacizumab to chemotherapy improved overall survival for those with advanced disease and residual cancer. Benefits were mostly seen in high-risk patients, not the general population.
Researchers found that phospholipids in ascites fluid disrupt immune cell function, particularly NK cells, leading to impaired anti-tumor activity. Blocking these lipids can restore NK cell activity, providing a promising therapeutic target.
A study found that removing ovaries and fallopian tubes in women with BRCA1 and BRCA2 genetic variants significantly reduces the risk of early death from cancer. This procedure, known as bilateral salpingo-oophorectomy (BSO), also decreases the risk of developing a second cancer without any serious side effects.
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Adaptive NK cells exhibit tumor-specific immune memory and cytotoxicity in ovarian cancer, making them promising for cancer treatment. The study challenges previous perceptions of NK cells, which have historically been considered only innate immune cells with no memory function against cancer.
Hyperbaric oxygen treatment has been shown to provide long-term relief for patients with late radiation-induced injuries, improving symptoms of urinary incontinence, bleeding, and severe pain. The treatment can lead to the healing of chronic injuries and allow patients to live a fully normal life.
Researchers have shed light on how a new type of antibody treatment works against ovarian cancer by reactivating patients' immune cells. The study shows that MOv18 IgE reverses the suppression of immune cells and induces them to kill cancer cells, providing new insights into this therapy.
A Phase 3 trial found that ChemoID improves objective response rates, median progression-free survival, and duration of response in patients with recurrent platinum-resistant ovarian cancer. The test identifies effective treatments by challenging cancer stem cells against specific anticancer drugs.
A 'master regulator' gene, ZNFX1, has been identified that may help guide treatment in patients with therapy-resistant ovarian cancer. The expression of this biomarker correlates with improved survival outcomes.
Researchers at MIT have developed a method to mass manufacture nanoparticles that target cancer cells, eliminating the need for manual polymer mixing and streamlining production. This approach integrates good manufacturing practice (GMP)-compliant processes, making it suitable for large-scale production of cancer treatments.
Patients from American Indian and Black communities are less likely to have elevated CA-125 levels at diagnosis, suggesting current thresholds may miss diverse patients. Inclusive diagnostic guidelines are needed to address disparities in ovarian cancer diagnosis and treatment.